Latest & greatest articles for latanoprost

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on latanoprost or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on latanoprost and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for latanoprost

1. Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Full Text available with Trip Pro

Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment (...) persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Lafuma A, Salmon JF, Robert J, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

2011 NHS Economic Evaluation Database.

2. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Full Text available with Trip Pro

Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Peeters A, Schouten JS, Severens JL, Hendrikse F, Prins MH, Webers CA Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. CRD summary The study examined the cost-effectiveness of first-line (...) treatment with either latanoprost or timolol for the management of ocular hypertension. The authors concluded that treatment starting with latanoprost was not cost-effective compared with treatment starting with timolol because of small differences in health benefits and the high price of latanoprost. The analysis was based on a valid modelling framework. The authors’ conclusions appear robust. Type of economic evaluation Cost-effectiveness analysis Study objective The study examined the cost

2012 NHS Economic Evaluation Database.

3. Monoprost - latanoprost - glaucoma and ocular hypertension

Monoprost - latanoprost - glaucoma and ocular hypertension latanoprost | CADTH.ca Find the information you need latanoprost latanoprost Last Updated: May 17, 2018 Result type: Reports Project Number: SR0541-000 Product Line: Generic Name: latanoprost Brand Name: Monoprost Manufacturer: Laboratoires Théa Indications: glaucoma and ocular hypertension Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: April 24, 2018 Recommendation Type: Reimburse with clinical

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

4. Latanoprost

Latanoprost Top results for latanoprost - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for latanoprost The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

5. Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension

Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development (...) as these outputs are produced as required for our stakeholders. > > > Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension September 2017 Glaucoma describes a group of disorders characterised by sight loss. Glaucoma is generally associated with high pressure in the liquids inside the eye but it can happen when the pressure level is normal. Individuals with consistently high eye pressure are at risk of developing

2017 NIHR Innovation Observatory

6. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials

Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

7. Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database

Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients (...) in comparison with a fixed combination of latanoprost and timolol (LT) as first-line therapy for ocular hypertension or glaucoma. The authors concluded that first-line treatment with travoprost was maintained longer than LT and halved the cost of care, but differences in the disease severity between the two groups might have affected the validity of these findings. The study had some methodological limitations and caution is required when interpreting the authors’ conclusions. Type of economic evaluation

2009 NHS Economic Evaluation Database.

8. Latanoprost + timolol (Fixapost) Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Latanoprost + timolol (Fixapost) Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. Published 13 May 2019 Product update SMC2159 latanoprost 50 micrograms/mL plus timolol 5mg/mL preservative free eye drops (Fixapost®) Thea Pharmaceuticals Limited 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises (...) NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission latanoprost plus timolol (Fixapost®) is accepted for restricted use within NHSScotland. Indication under review: reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. SMC restriction: to use

2019 Scottish Medicines Consortium

9. Efficacy of Topical Latanoprost Versus Minoxidil and Betamethasone Valerate on The Treatment of Alopecia Areata. (Abstract)

Efficacy of Topical Latanoprost Versus Minoxidil and Betamethasone Valerate on The Treatment of Alopecia Areata. Alopecia areata (AA) is one of the most common causes of localized hair loss. There is no universally proven therapy that induces and sustains remission of hair growth in AA.To compare the efficacy and safety of topical latanoprost, minoxidil and betamethasone valerate on hair growth in patients with AA.Hundred patients with AA classified into five groups of 20 treated with: Group I (...) , latanoprost 0.1% lotion; Group II, minoxidil 5% lotion; Group III, betamethasone valerate 0.1% solution; Group IV, combination of latanoprost lotion and betamethasone valerate solution and Group V, a vehicle lotion control group.There was a statistically significant improvement in all therapeutic groups when compared with control group and reduction of severity of alopecia tool score of scalp and beard before and after treatment for all therapeutic groups.Latanoprost, minoxidil and betamethasone valerate

2017 Journal of Dermatological Treatment Controlled trial quality: uncertain

10. Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma. Full Text available with Trip Pro

Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma. To evaluate the efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma (CACG).Pertinent publications were identified through systematic searches of PubMed, EMBASE, the Cochrane Controlled Trials Register and the Chinese Biomedicine Database. Randomized controlled trials comparing latanoprost (...) 5.2 software.Five published randomized controlled trials involving 528 patients were included in the present meta-analysis. The IOP reduction (IOPR) was significantly greater in the latanoprost group than in the timolol group at diurnal curve (WMD: 2.22 mmHg [95% CI, 1.65 to 2.79], P < 0.00001), peak (WMD: 2.44 mmHg [0.85 to 4.03], P = 0.003) and trough (WMD: 2.67 mmHg [1.93 to 3.41], P < 0.00001). Timolol caused conjunctival hyperemia in less patients than latanoprost (pooled OR: 2.74 [95% CI

2014 Current medical research and opinion

11. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension Zhang W Y, Po A L, Dua H (...) S, Azuara-Blanco A Authors' objectives To evaluate the efficacy and tolerance of latanoprost in comparison with timolol for open angle glaucoma and ocular hypertension. Searching MEDLINE, EMBASE and the Science Citation Index were searched from 1966 to July 2000. The search terms and strategies were described in the report. The bibliographies of studies and reviews were checked. The manufacturers' databases, including the Pharmacia Upjohn ophthalmology database and the Merck glaucoma database

2001 DARE.

12. [Prospects of using latanoprost, prostaglandin F2 alpha analog, in hypotensive therapy for glaucoma]. (Abstract)

[Prospects of using latanoprost, prostaglandin F2 alpha analog, in hypotensive therapy for glaucoma]. Hypotensive efficacy and tolerance of a new antiglaucoma drug lathanoprost, a 0.005% xalathane solution, prostaglandin F2 alpha analog, is studied. A single instillation of xalathane decreased ophthalmic tone in normal subjects and glaucoma patients with increased intraocular pressure. Combination of the drug with other hypotensive agents (pilocarpine + timolol) amplified their hypotensive

1998 Vestnik oftalmologii Controlled trial quality: uncertain

13. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Full Text available with Trip Pro

Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Treatments for open-angle glaucoma aim to prevent vision loss through lowering of intraocular pressure, but to our knowledge no placebo-controlled trials have assessed visual function preservation, and the observation periods of previous (unmasked) trials have typically been at least 5 years. We assessed vision preservation in patients given latanoprost compared with those given placebo.In (...) this randomised, triple-masked, placebo-controlled trial, we enrolled patients with newly diagnosed open-angle glaucoma at ten UK centres (tertiary referral centres, teaching hospitals, and district general hospitals). Eligible patients were randomly allocated (1:1) with a website-generated randomisation schedule, stratified by centre and with a permuted block design, to receive either latanoprost 0·005% (intervention group) or placebo (control group) eye drops. Drops were administered from identical bottles

2014 Lancet Controlled trial quality: predicted high

14. Comparison of the Effects of Dorzolamide/Timolol Fixed Combination versus Latanoprost on Intraocular Pressure and Ocular Perfusion Pressure in Patients with Normal-Tension Glaucoma: A Randomized, Crossover Clinical Trial. Full Text available with Trip Pro

Comparison of the Effects of Dorzolamide/Timolol Fixed Combination versus Latanoprost on Intraocular Pressure and Ocular Perfusion Pressure in Patients with Normal-Tension Glaucoma: A Randomized, Crossover Clinical Trial. To assess the noninferiority of a dorzolamide-timolol fixed combination (DTFC) versus latanoprost in terms of intraocular pressure (IOP) and to compare blood pressure (BP), ocular perfusion pressure (OPP) and diastolic ocular perfusion pressure (DOPP) between the latanoprost (...) and DTFC groups in patients with normal-tension glaucoma (NTG).Prospective, interventional, randomized, single-blinded, crossover design study. Patients with newly diagnosed NTG that had not been treated with a glaucoma medication in the most recent 2 months were recruited. In total, 44 patients with NTG were randomly allocated to one of two groups. Patients in group A were treated with DTFC, lubricant, and latanoprost for 4 weeks each, whereas patients in group B were treated with latanoprost

2016 PloS one Controlled trial quality: uncertain

15. The Effects of Fixed Combination of Bimatoprost-Timolol and Travoprost-Timolol on Intraocular Pressure in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension, Previously on Nonfixed Combination of Latanoprost and Timolol. (Abstract)

The Effects of Fixed Combination of Bimatoprost-Timolol and Travoprost-Timolol on Intraocular Pressure in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension, Previously on Nonfixed Combination of Latanoprost and Timolol. To compare the effects of fixed combination of bimatoprost-timolol and travoprost-timolol on intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.This was a prospective, randomized, observer-masked, crossover parallel (...) comparison trial.Forty-one patients with primary open-angle glaucoma or ocular hypertension on nonfixed combination of latanoprost and timolol with IOP of 21 mm Hg or less were randomized to either bimatoprost-timolol or travoprost-timolol fixed combinations for 8-week treatment period. Intraocular pressure was measured at 8 AM, 12 PM, 4 PM, and 8 PM at the baseline and at the end point. Conjunctiva hyperemia and superficial punctate keratopathy after treatment with each fixed combination therapy were

2015 Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) Controlled trial quality: uncertain

16. Latanoprost (Xalatan): increased reporting of eye irritation since reformulation

Latanoprost (Xalatan): increased reporting of eye irritation since reformulation Latanoprost (Xalatan): increased reporting of eye irritation since reformulation - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Latanoprost (Xalatan): increased reporting of eye irritation since reformulation Advise patients to tell their health professional if they experience severe eye irritation. Published 20 July 2015 From: Therapeutic area: When prescribing or dispensing the Xalatan brand (...) of latanoprost: advise patients to tell their health professional if they experience severe eye irritation review treatment if patients mention severe eye irritation please continue to report suspected side effects to latanoprost or any other medicines on a Xalatan is an eye-drop formulation of latanoprost. It is licensed for the reduction of intraocular pressure in adults and children with ocular hypertension and open angle glaucoma. In 2013, the Xalatan pH was reduced from 6.7 to 6.0 to allow for long-term

2015 MHRA Drug Safety Update

17. Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing

2017 Clinical Trials

18. A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients. Full Text available with Trip Pro

A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients. The aim of the present study was to compare the confocal and clinical features of newly diagnosed glaucoma patients receiving unpreserved prostaglandins (tafluprost) versus preserved prostaglandins (latanoprost).40 patients were randomized to tafluprost 0.0015% (20 patients; 32 eyes) or latanoprost 0.005% + benzalkonium chloride 0.02% (20 patients; 35 eyes) once (...) being negative, subtle changes were present. During follow-up, all eyes without nerve branching pattern at baseline progressively developed it when treated with latanoprost, whereas no change occurred using tafluprost treatment (p = 0.05). None of the eyes without beading at baseline developed it at the end of the study in the tafluprost group, whereas beading did occur in 75% of patients treated with latanoprost (p = 0.05). Both treatments were associated with increased keratocyte activation

2015 Advances in therapy Controlled trial quality: uncertain

19. Latanoprost Induced Iris Pigment Epithelial and Ciliary Body Cyst Formation in Hypermetropic Eyes Full Text available with Trip Pro

Latanoprost Induced Iris Pigment Epithelial and Ciliary Body Cyst Formation in Hypermetropic Eyes Latanoprost has become one of the most widely prescribed topical antihypertensive medications in recent years. Yet there have been few reports of secondary iris pigment epithelial (IPE) and ciliary body (CB) cyst formation to date and none, to our knowledge, reported in eyes predisposed to primary angle closure.We report the first documented case of bilateral IPE and CB cysts in a hypermetropic (...) patient with prior laser peripheral iridotomies (LPIs) as a rare, delayed side effect of topical Latanoprost treatment. The cysts subsided with discontinuation of Latanoprost, thereby demonstrating a causal relationship. We discuss the pathogenesis of such cysts and advocate using of serial ultrasound biomicroscopic (UBM) images to monitor them.Latanoprost may cause iris pigment epithelial and ciliary body cysts that remain clinically undetected. In eyes predisposed to angle closure, such cysts may

2017 Case reports in ophthalmological medicine

20. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension. Full Text available with Trip Pro

Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension. This study compared the efficacy, safety, and pharmacokinetics of a preservative-free latanoprost formulation to an established, benzalkonium chloride (BAK) containing formulation for the treatment of open-angle glaucoma or ocular hypertension.This was a phase II, randomized, cross-over, investigator-masked, multi-center, pilot study (NCT01494753). A total of 30 untreated adult (...) patients (aged ≥18 years) with primary open angle glaucoma, pseudo-exfoliative glaucoma, pigmentary glaucoma, or ocular hypertension received either preservative-free or preserved latanoprost once daily in both eyes for 6 weeks, before crossing over to receive the other treatment. Efficacy (intraocular pressure [IOP] at 8 am, midday, 4 pm and 8 pm, and global efficacy assessment by investigator), safety (adverse events, ocular symptoms and global tolerance, slit lamp examination, funduscopy, visual

2017 Current medical research and opinion Controlled trial quality: uncertain